Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Pays $31.5 Million Upfront, Plus Milestones To Access Angiochem’s Rare Disease Technologies

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline takes aim at neurological symptoms of lysosomal storage diseases, increasing likely future competitive pressure on Sanofi's and Shire's rare disease products.

You may also be interested in...

Geron Restructuring Sours Investors As Company Bets On Cancer

The pioneering U.S. biotech will look to partner its five human embryonic stem cell research programs while focusing entirely on two mid-stage cancer assets.

Going Deeper Into Rare Disease, GSK Takes Reins of Amicus Fabry Program

Even with Phase III trial delays, Glaxo pays $60 million upfront for worldwide rights to Amigal and takes a minority stake in its developer.

GSK Argues Its Strategy Is Delivering As It Makes More Cuts, Including In R&D

GlaxoSmithKline CEO Andrew Witty declared on Feb. 4 that his strategy of building a global, diversified business was delivering. And to prove his point, he announced a return to full-year sales growth in 2009 after a negative 2008, and an upbeat forecast for 2010 as well


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts